TY - JOUR
AB - Breast Cancer Res Treat (2018) 167:309–405 https://doi.org/10.1007/s10549-017-4585-x AB STRACTS 1st UK Interdisciplinary Breast Cancer Symposium—15th–16th January 2018 Published online: 10 January 2018 Springer Science+Business Media, LLC, part of Springer Nature 2018 Contents Invited presentations Selected oral presentations: O01-O14 Poster presentations: • Clinical Biomarker: P1.1-P1.40 • Pathology: P2.1-P2.15 • Clinical Early Disease: P3.1-P3.24 • Diagnostics Imaging: P4.1-P4.6 • Epidemiology and Prevention: P5.1-P5.11 • Patient Centred Care: P6.1-P6.24 • Clinical Late Disease: P7.1-P7.7 • Trials in Progress: P8.1-P8.11 • Pre-Clinical New Treatments: P9.1-P9.9 • Pre-Clinical Biological Studies: P10.1-P10.44 123 310 Breast Cancer Res Treat (2018) 167:309–405 mortality. Long-term morbidity from WBRT is very unusual but does Highlights of 2017 (II)—Early Disease occur and the small risks of cardiac toxicity and carcinogenesis need to be considered. Professor Michael Gnant, MD, FACS The publication of results derived from selected cohorts of patients Medical University of Vienna, Vienna, Austria with very low recurrence rates without WBRT has encouraged many to focus attention on improvements in surgical techniques and margin A number of important large clinical trials in the field of early breast assessment as a means of avoiding a need for WBRT. Unfortunately cancer (EBC) reported results at large international meetings such as the 
TI - 1st UK Interdisciplinary Breast Cancer Symposium—15th–16th January 2018
JF - Breast Cancer Research and Treatment
DO - 10.1007/s10549-017-4585-x
DA - 2018-01-10
UR - https://www.deepdyve.com/lp/springer-journals/1st-uk-interdisciplinary-breast-cancer-symposium-15th-16th-january-0gaGOOdMCV
SP - 309
EP - 405
VL - 167
IS - 1
DP - DeepDyve
ER -